Merck, 99072806-1VL, ATDC5

Application
ATDC5 has been used to study cartilage differentiation.
Biochem/physiol Actions
Mouse 129 teratocarcinoma AT805 derived
The chondrogenic cell line ATDC5 has been derived from teratocarcinoma AT805. Cells showed a sequential transition of phenotype in vitro. They encompass stages from mesenchymal condensation to calcification. Bone morphogenetic protein-2 (BMP-2) stimulated the sequential progression of early- and late-phase differentiation. Activation of parathyroid hormone (PTH)/PTH-related peptide (PTHrP) receptor resulted in inhibition of this differentiation capacity.
Preparation Note
DMEM: Ham′s F12 (1:1) + 2mM Glutamine + 5% Foetal Bovine Serum (FBS).
Split sub-confluent cultures (70-80%) i.e. seeding at 1-3 x 10,000 cells/cm² using 0.25% trypsin or trypsin/EDTA;CO₂; 37°C subculture every 2-3 days.
Other Notes
Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.
This cell line is part of the European Collection of Authenticated Cell Cultures (ECACC), an international repository managed by the United Kingdom Health Security Agency (UKHSA). No licensing agreement is required when either this cell line or the DNA extracted from it are used for internal research purposes only. Any other use of these products is prohibited without the express written permission of UKHSA. Inquiries regarding authorized use of this cell line or its genomic DNA may be directed to [email protected].